The Curse of Being First: Lessons From Pharma’s Blockbuster Drugs
What can we learn from Biogen's decision to halt sales of aducanumab?
Read More
The Costs of Alzheimer's Disease and the Value of Effective Therapies
Current Implications for the Managed Care of Dementia